GOLD 2011 disease severity classification in COPDGene: A prospective cohort study

MeiLan K. Han, Hana Muellerova, Douglas Curran-Everett, Mark T. Dransfield, George R. Washko, Elizabeth A. Regan, Russell P. Bowler, Terri L Beaty, John E. Hokanson, David A. Lynch, Paul W. Jones, Antonio Anzueto, Fernando J. Martinez, James D. Crapo, Edwin K. Silverman, Barry J. Make

Research output: Contribution to journalArticle

Abstract

Background: The 2011 GOLD (Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease [COPD]) consensus report uses symptoms, exacerbation history, and forced expiratory volume (FEV1)% to categorise patients according to disease severity and guide treatment. We aimed to assess both the influence of symptom instrument choice on patient category assignment and prospective exacerbation risk by category. Methods: Patients were recruited from 21 centres in the USA, as part of the COPDGene study. Eligible patients were aged 45-80 years, had smoked for 10 pack-years or more, and had an FEV1/forced vital capacity (FVC) 1% predicted ≥50 vs

Original languageEnglish (US)
Pages (from-to)43-50
Number of pages8
JournalThe Lancet Respiratory Medicine
Volume1
Issue number1
DOIs
StatePublished - Mar 2013

Fingerprint

Cohort Studies
Prospective Studies
Vital Capacity
Forced Expiratory Volume
Chronic Obstructive Pulmonary Disease
History
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Han, M. K., Muellerova, H., Curran-Everett, D., Dransfield, M. T., Washko, G. R., Regan, E. A., ... Make, B. J. (2013). GOLD 2011 disease severity classification in COPDGene: A prospective cohort study. The Lancet Respiratory Medicine, 1(1), 43-50. https://doi.org/10.1016/S2213-2600(12)70044-9

GOLD 2011 disease severity classification in COPDGene : A prospective cohort study. / Han, MeiLan K.; Muellerova, Hana; Curran-Everett, Douglas; Dransfield, Mark T.; Washko, George R.; Regan, Elizabeth A.; Bowler, Russell P.; Beaty, Terri L; Hokanson, John E.; Lynch, David A.; Jones, Paul W.; Anzueto, Antonio; Martinez, Fernando J.; Crapo, James D.; Silverman, Edwin K.; Make, Barry J.

In: The Lancet Respiratory Medicine, Vol. 1, No. 1, 03.2013, p. 43-50.

Research output: Contribution to journalArticle

Han, MK, Muellerova, H, Curran-Everett, D, Dransfield, MT, Washko, GR, Regan, EA, Bowler, RP, Beaty, TL, Hokanson, JE, Lynch, DA, Jones, PW, Anzueto, A, Martinez, FJ, Crapo, JD, Silverman, EK & Make, BJ 2013, 'GOLD 2011 disease severity classification in COPDGene: A prospective cohort study', The Lancet Respiratory Medicine, vol. 1, no. 1, pp. 43-50. https://doi.org/10.1016/S2213-2600(12)70044-9
Han MK, Muellerova H, Curran-Everett D, Dransfield MT, Washko GR, Regan EA et al. GOLD 2011 disease severity classification in COPDGene: A prospective cohort study. The Lancet Respiratory Medicine. 2013 Mar;1(1):43-50. https://doi.org/10.1016/S2213-2600(12)70044-9
Han, MeiLan K. ; Muellerova, Hana ; Curran-Everett, Douglas ; Dransfield, Mark T. ; Washko, George R. ; Regan, Elizabeth A. ; Bowler, Russell P. ; Beaty, Terri L ; Hokanson, John E. ; Lynch, David A. ; Jones, Paul W. ; Anzueto, Antonio ; Martinez, Fernando J. ; Crapo, James D. ; Silverman, Edwin K. ; Make, Barry J. / GOLD 2011 disease severity classification in COPDGene : A prospective cohort study. In: The Lancet Respiratory Medicine. 2013 ; Vol. 1, No. 1. pp. 43-50.
@article{1bc629fbda3a4e3dad33984064000254,
title = "GOLD 2011 disease severity classification in COPDGene: A prospective cohort study",
abstract = "Background: The 2011 GOLD (Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease [COPD]) consensus report uses symptoms, exacerbation history, and forced expiratory volume (FEV1){\%} to categorise patients according to disease severity and guide treatment. We aimed to assess both the influence of symptom instrument choice on patient category assignment and prospective exacerbation risk by category. Methods: Patients were recruited from 21 centres in the USA, as part of the COPDGene study. Eligible patients were aged 45-80 years, had smoked for 10 pack-years or more, and had an FEV1/forced vital capacity (FVC) 1{\%} predicted ≥50 vs",
author = "Han, {MeiLan K.} and Hana Muellerova and Douglas Curran-Everett and Dransfield, {Mark T.} and Washko, {George R.} and Regan, {Elizabeth A.} and Bowler, {Russell P.} and Beaty, {Terri L} and Hokanson, {John E.} and Lynch, {David A.} and Jones, {Paul W.} and Antonio Anzueto and Martinez, {Fernando J.} and Crapo, {James D.} and Silverman, {Edwin K.} and Make, {Barry J.}",
year = "2013",
month = "3",
doi = "10.1016/S2213-2600(12)70044-9",
language = "English (US)",
volume = "1",
pages = "43--50",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - GOLD 2011 disease severity classification in COPDGene

T2 - A prospective cohort study

AU - Han, MeiLan K.

AU - Muellerova, Hana

AU - Curran-Everett, Douglas

AU - Dransfield, Mark T.

AU - Washko, George R.

AU - Regan, Elizabeth A.

AU - Bowler, Russell P.

AU - Beaty, Terri L

AU - Hokanson, John E.

AU - Lynch, David A.

AU - Jones, Paul W.

AU - Anzueto, Antonio

AU - Martinez, Fernando J.

AU - Crapo, James D.

AU - Silverman, Edwin K.

AU - Make, Barry J.

PY - 2013/3

Y1 - 2013/3

N2 - Background: The 2011 GOLD (Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease [COPD]) consensus report uses symptoms, exacerbation history, and forced expiratory volume (FEV1)% to categorise patients according to disease severity and guide treatment. We aimed to assess both the influence of symptom instrument choice on patient category assignment and prospective exacerbation risk by category. Methods: Patients were recruited from 21 centres in the USA, as part of the COPDGene study. Eligible patients were aged 45-80 years, had smoked for 10 pack-years or more, and had an FEV1/forced vital capacity (FVC) 1% predicted ≥50 vs

AB - Background: The 2011 GOLD (Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease [COPD]) consensus report uses symptoms, exacerbation history, and forced expiratory volume (FEV1)% to categorise patients according to disease severity and guide treatment. We aimed to assess both the influence of symptom instrument choice on patient category assignment and prospective exacerbation risk by category. Methods: Patients were recruited from 21 centres in the USA, as part of the COPDGene study. Eligible patients were aged 45-80 years, had smoked for 10 pack-years or more, and had an FEV1/forced vital capacity (FVC) 1% predicted ≥50 vs

UR - http://www.scopus.com/inward/record.url?scp=84877102716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877102716&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(12)70044-9

DO - 10.1016/S2213-2600(12)70044-9

M3 - Article

C2 - 24321803

AN - SCOPUS:84877102716

VL - 1

SP - 43

EP - 50

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 1

ER -